Business Wire · MANE · November 8, 2026

Veradermics to Hold Conference Call to Discuss 12-Month Long-Term Results from Phase 3 ‘302' Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss

Get the app for more

Explore stock news, insights and company research.